Jarushka Naidoo: Can intratumor eschericia improve OS from ICIs in NSCLC
Jarushka Naidoo shared a post on X:
”Can intratumor eschericia (E) bring immune cells to the tumor and improve OS from ICIs in NSCLC? Yes:
- 958patient discovery and 722patient validation cohorts.
- E is associated with increased OS (16 vs. 11 months, p=0.006) from ICI monotherapy in both cohorts.
A privilege to serve as reviewer for this paper and well done to all authors.”
Authors: Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S. Bowman, Ayyüce Begüm Bektaş, Martina Bradic, Wenfei Kang, Eric Chan, Pooja Gogia, Katia Manova-Todorova, Douglas A. Mata, Jacklynn V. Egger, Hira Rizvi, Nicolas D. Socci, Daniel W. Kelly, Eric Rosiek, Fanli Meng, Grittney Tam, Ning Fan, Alexander Drilon, Helena A. Yu, Gregory J. Riely, Natasha Rekhtman, Álvaro Quintanal Villalonga, Snjezana Dogan, Umesh Bhanot, Mithat Gönen, Brian Loomis, Matthew D. Hellmann, Adam J. Schoenfeld, Marc Ladanyi, Charles M. Rudin, Chad M. Vanderbilt.
Source: Jarushka Naidoo/X
Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.